Literature DB >> 11747695

Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children.

M C Vela Coral1, N Fonseca, E Castañeda, J L Di Fabio, S K Hollingshead, D E Briles.   

Abstract

Pneumococcal surface protein A (PspA) elicits protection in mice against fatal bacteremia and sepsis caused by genetically diverse pneumococci and protects against carriage and lung infection. We determined the PspA families of invasive isolates of Streptococcus pneumoniae recovered from Colombian children <5 years of age. That 97.5% of Colombian isolates belong to PspA families 1 and 2 supports the hypothesis that a human PspA vaccine covering a few PspA families could be broadly effective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747695      PMCID: PMC2631885          DOI: 10.3201/eid0705.017510

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  23 in total

1.  Effects of active immunization with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media.

Authors:  P White; A Hermansson; C Svanborg; D Briles; K Prellner
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1999 Jul-Aug       Impact factor: 1.538

2.  Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.

Authors:  S K Hollingshead; R Becker; D E Briles
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

4.  Pneumococcal polysaccharide immunization in infants and children.

Authors:  M J Cowan; A J Ammann; D W Wara; V M Howie; L Schultz; N Doyle; M Kaplan
Journal:  Pediatrics       Date:  1978-11       Impact factor: 7.124

5.  Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine.

Authors:  B M Gray; H C Dillon; D E Briles
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

6.  A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.

Authors:  M Yamamoto; D E Briles; S Yamamoto; M Ohmura; H Kiyono; J R McGhee
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

Review 7.  Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).

Authors:  D E Briles; R C Tart; E Swiatlo; J P Dillard; P Smith; K A Benton; B A Ralph; A Brooks-Walter; M J Crain; S K Hollingshead; L S McDaniel
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

8.  Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: an overview. PAHO/Rockefeller University Workshop. Pan American Health Organization.

Authors:  A Tomasz; A Corso; E P Severina; G Echániz-Aviles; M C Brandileone; T Camou; E Castañeda; O Figueroa; A Rossi; J L Di Fabio
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

9.  Penicillin-resistant Streptococcus pneumoniae in Colombia: presence of international epidemic clones. Colombian pneumococcal study group.

Authors:  E Castañeda; I Peñuela; M C Vela; A Tomasz
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

10.  Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae.

Authors:  L S McDaniel; G Scott; J F Kearney; D E Briles
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  33 in total

1.  Contribution of serotype and genetic background to virulence of serotype 3 and serogroup 11 pneumococcal isolates.

Authors:  Lauren J McAllister; Abiodun D Ogunniyi; Uwe H Stroeher; Amanda J Leach; James C Paton
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

3.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

4.  PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  Christina M Croney; Mamie T Coats; Moon H Nahm; David E Briles; Marilyn J Crain
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

5.  Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil.

Authors:  Fabiana Cristina Pimenta; Fátima Ribeiro-Dias; Maria Cristina C Brandileone; Eliane N Miyaji; Luciana C C Leite; Ana Lúcia S Sgambatti de Andrade
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci.

Authors:  David E Briles; Lea Novak; Muneki Hotomi; Frederik W van Ginkel; Janice King
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

8.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

9.  Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition.

Authors:  M Darrieux; E N Miyaji; D M Ferreira; L M Lopes; A P Y Lopes; B Ren; D E Briles; S K Hollingshead; L C C Leite
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

10.  Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.

Authors:  Martina M Ochs; William Bartlett; David E Briles; Bryony Hicks; Audra Jurkuvenas; Peggy Lau; Bing Ren; Amanda Millar
Journal:  Microb Pathog       Date:  2007-10-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.